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ABSTRACT
ObjectiveaaAmple evidence has suggested that age at onset of Parkinson’s disease (PD) is associated with heterogeneous clinical 
features in individuals. We hypothesized that this may be attributed to different patterns of nigrostriatal dopamine loss.
MethodsaaA total of 205 consecutive patients with de novo PD who underwent 18F-FP-CIT PET scans (mean follow-up duration, 
6.31 years) were divided into three tertile groups according to their age at onset of parkinsonian motor symptoms. Striatal dopa-
mine transporter (DAT) availability was compared between the old- (n = 73) and young-onset (n = 66) groups. In addition, the 
risk of developing freezing of gait (FOG) and longitudinal requirements for dopaminergic medications were examined.
ResultsaaThe old-onset PD group (mean age at onset, 72.66 years) exhibited more severe parkinsonian motor signs than the 
young-onset group (52.58 years), despite comparable DAT availability in the posterior putamen; moreover, the old-onset group 
exhibited more severely decreased DAT availability in the caudate than the young-onset group. A Cox regression model revealed 
that the old-onset PD group had a higher risk for developing FOG than the young-onset group [hazard ratio 2.523, 95% confi-
dence interval (1.239–5.140)]. The old-onset group required higher doses of dopaminergic medications for symptom control than 
the young-onset group over time.
ConclusionaaThe present study demonstrated that the old-onset PD group exhibited more severe dopamine loss in the caudate 
and were more likely to develop gait freezing, suggesting that age at onset may be one of the major determinants of the pattern of 
striatal dopamine depletion and progression of gait disturbance in PD.
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There is mounting evidence that Parkinson’s disease (PD) is 
a heterogeneous disorder rather than a single disease entity.1 
The identification of PD subtypes has received one of the high-
est priority recommendations in clinical research for PD because 
it may help to understand underlying disease mechanisms, pre-
dict disease course, and facilitate the design of more efficient 
personalized therapeutic strategies.2 Consequently, several stud-
ies have attempted to delineate PD subtypes;3,4 ample evidence 
has suggested that age at onset is a major determinant of clinical 
heterogeneity in patients with PD.4-7 Although the age cut-offs 
used to define “young-onset PD” and “old-onset PD” vary 
among studies, the most consistent findings have been slower 
disease progression, better response to levodopa, more frequent 
motor complications, and less frequent cognitive impairment in 
patients with young-onset PD versus those with old-onset PD.5
However, the exact mechanism underlying the age-at-onset-
dependent differences in PD remains largely unknown. Given 
that different clinical subtypes of PD are associated with hetero-
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geneous patterns of pathological involvement,8,9 there may be 
differences in the patterns of degeneration of dopaminergic 
neurons between patients with young- and old-onset PD. To 
date, few reports have demonstrated that age at onset is related 
to different patterns of striatal dopamine depletion in PD;10-13 
however, these studies were limited by small sample sizes,10 the 
confounding effects of PD medications,11,12 and less detailed 
segmentation of the striatum.10-13 Therefore, in the present study, 
we compared the availability of striatal dopamine transporter 
(DAT) between patients with young- and old-onset de novo 
PD, with more detailed striatal segmentation. Additionally, we 
tested whether the age at onset of PD was associated with the 
rate of disease progression. To do this, we examined long-term 
motor outcomes in relation to the risk of developing freezing of 
gait (FOG) and in relation to the longitudinal requirement of 
dopaminergic medications over time according to the age at 
onset of PD.
MATERIALS & METHODS
Subjects
The medical records of 252 consecutive patients with de novo 
PD who visited the movement disorders outpatient clinic from 
April 2009 to June 2013 were reviewed. Of these, 47 patients who 
were lost to follow-up within 3 years were excluded. PD was di-
agnosed according to the clinical diagnostic criteria of the Unit-
ed Kingdom PD Society Brain Bank, and all patients exhibited 
decreased striatal DAT availability on 18F-N-(3-fluoropropyl)-
2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) 
positron emission tomography (PET) at the baseline evaluation. 
Parkinsonian motor symptoms were assessed using the Unified 
Parkinson’s Disease Rating Scale Part III (UPDRS-III). The Ko-
rean version of the Mini-Mental State Examination (K-MMSE) 
was used to assess general cognition. The doses of PD medica-
tions were calculated as levodopa-equivalent doses (LEDs).14 
The patients were then classified according to the age at onset 
of parkinsonian symptoms. Given that age cut-offs to classify 
patients as either young-onset PD or old-onset PD have not yet 
been established,5 a total of 205 patients with de novo PD were 
subdivided into tertile groups according to their age at onset of 
their parkinsonian symptoms. Sixty-six patients were assigned 
to the young-onset PD group [the lowest tertile group (age at 
onset < 58 years)], and 73 were assigned to the old-onset PD 
group [the highest tertile group (age at onset > 66 years)]. We 
additionally recruited 20 age- and sex-matched healthy controls 
who underwent 18F-FP-CIT PET scans. The healthy controls 
were divided into the young control group (n = 10; mean age, 
53.20 ± 2.82 years; female, 50.0%) and the old control group (n 
= 10; mean age, 71.40 ± 4.38 years; female 50.0%) and were com-
pared with the respective age-matched PD groups. This study 
was approved by our Institutional Review Board (IRB no. 4- 
2014-0637). Given the retrospective nature of the present study, 
requirements for informed consent were waived.
Quantitative analyses of 18F-FP-CIT PET images
18F-FP-CIT PET was performed using a Discovery 600 (GE 
Healthcare, Milwaukee, WI, USA) device, which acquires im-
ages with a three-dimensional resolution of 2.3 mm full-width at 
half-maximum. After a 6-hour fast, subjects were intravenous-
ly injected with 5 mCi (185 MBq) of 18F-FP-CIT. Ninety min-
utes after the injection, PET images were acquired for 20 min-
utes in the three-dimensional mode, and spiral CT images were 
obtained for attenuation correction with 120 kVp and a current 
of 200 mA.
We performed quantitative analyses of 18F-FP-CIT PET data 
as previously described.15 We performed image processing us-
ing SPM8 (Wellcome Department of Imaging Neuroscience, 
Institute of Neurology, UCL, London, United Kingdom) and 
MATLAB 2013a (MathWorks, Natick, MA, USA) for Windows. 
Volumes of interest (VOI) were defined based on the template 
in standard space. Reconstructed PET images were then spa-
tially normalized to the Montreal Neurology Institute template 
space using a standard 18F-FP-CIT PET template, which was 
generated from T1-weighted magnetic resonance (T1 MR) and 
18F-FP-CIT PET images of 13 healthy controls. Twelve VOI of 
the striatal subregions and one occipital VOI were drawn on a 
coregistered spatially normalized single T1 MR and 18F-FP-CIT 
PET template image using MRIcro version 1.37 (Chris Rorden, 
Columbia, SC, USA). The striatal subregions consisted of the 
anterior/posterior caudate, anterior/posterior putamen, ventral 
putamen, and ventral striatum. The boundaries of the striatal 
subregions were defined as described in our previous work.16 
These VOI were adjusted using a minor translation with the 
editing software ANIQUE.17 DAT availability was calculated 
according to the nondisplaceable binding potential as follows: 
[mean standardized uptake value (SUV) of the striatal subre-
gion VOI – mean SUV of the occipital VOI] / (mean SUV of 
the occipital VOI). We also calculated the intersubregional ra-
tio for the anterior posterior gradient (i.e., caudate to posterior 
putamen).
Assessment of the development of FOG during the 
follow-up period
FOG is defined as an unintentional and temporary phenom-
enon in which the feet fail to progress forward despite the in-
tention to walk,18 and its appearance has been associated with 
disease progression.19 Various FOG subtypes have been identi-
fied: start hesitation; freezing on turning; freezing in restricted 
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areas; destination freezing; and open space hesitation. Patients 
were asked about the development of FOG at every visit. Gait 
was also inspected (“medication on” status) at the outpatient 
clinic, where patients were specifically asked about the charac-
teristic subjective sensation of the feet becoming “glued to the 
floor” in either the on or off state. The time from parkinsonian 
symptoms onset to the development of FOG was assessed using 
Kaplan-Meier estimates, and a log-rank test was used to com-
pare the Kaplan-Meier curves between the PD groups. A Cox 
regression model was used to estimate the hazard ratio (HR) 
and corresponding 95% confidence interval (CI) while adjust-
ing for sex, DAT availability (either in the posterior putamen or 
caudate), LED at the development of FOG or at last visit to the 
outpatient clinic, and K-MMSE scores. A log-minus-log plot 
and time-dependent covariate analysis revealed that the as-
sumption of proportionality was reasonable.
Assessment of longitudinal changes in the dose of 
dopaminergic medications over time
In this study, patients with PD visited the outpatient clinic at 
three-month intervals for at least 3 years; the doses of PD medi-
cations were adjusted for effective symptom management ac-
cording to patients’ response. A linear mixed model was used 
to compare the rate of longitudinal changes in LEDs between 
the two PD groups. Four fixed effects were included in the 
model: three were between-subject effects (PD group accord-
ing to age at PD onset, sex, and baseline UPDRS-III scores), 
and one was a within-subject effect (time). Time was treated as 
a categorical variable with a 6-month interval (0 to 36) because 
most of the increases in LED occurred within the first 6 months, 
and then the doses of PD medications were adjusted every 3 
months thereafter. The effects of the PD group on longitudinal 
changes in LED were tested using a time × PD group interac-
tion term.
Statistical analyses
The baseline demographic characteristics of subjects in the 
PD groups were compared using Student’s t-tests and Pearson’s 
χ2 tests for continuous and categorical variables, respectively. 
To compare DAT availability in each striatal subregion, Student’s 
t-test with Bonferroni correction for multiple comparisons was 
used. The effects of age at PD onset on the development of FOG 
were assessed using a log-rank test and the Cox regression mod-
el as described above. A linear mixed model was used to com-
pare the rate of longitudinal changes in LED between the PD 
groups. Statistical analyses were performed using SPSS version 
23.0 (IBM Corp., Armonk, NY, USA); statistical significance 
was set at p < 0.05 (two-tailed).
RESULTS
Baseline clinical characteristics and striatal DAT 
availability in patients with PD
The patients in the old-onset PD group [mean (± SD) age at 
onset of PD, 72.66 ± 4.71 years; mean age at PD diagnosis, 73.80 
± 4.94 years] were older than those in the young-onset PD 
group (51.15 ± 5.06 years, p < 0.001; age at PD diagnosis, 52.58 
± 5.00 years, p < 0.001). Patients in the old-onset PD group 
had higher UPDRS-III scores (24.26 ± 10.01) than those in the 
young-onset PD group (20.79 ± 9.68; p = 0.040). The old-onset 
PD group had lower K-MMSE scores (26.77 ± 1.78) than the 
young-onset PD group (27.58 ± 2.02; p = 0.013). There were no 
significant differences in sex or disease duration between the 
groups (Table 1).
DAT availability in each striatal subregion in the PD groups 
is also presented in Table 1. The old-onset PD group exhibited 
more severely decreased DAT availability in the caudate than 
the young-onset PD group (anterior caudate, 1.91 ± 0.58 vs. 2.50 
± 0.70, p < 0.001; posterior caudate, 1.19 ± 0.40 vs. 1.55 ± 0.51, 
p < 0.001), while DAT availability in the other striatal subre-
gions (anterior putamen, posterior putamen, ventral putamen, 
and ventral striatum) did not differ between the groups. The 
old-onset PD group showed a lower ratio of caudate to posteri-
or putamen (1.46 ± 0.41) than the young-onset PD group (1.85 
± 0.47; p < 0.001). Additionally, there were no significant dif-
ferences in DAT availability of all striatal subregions between 
the old and young control groups (Supplementary Table 1 in 
the online-only Data Supplement). The old control group also 
had a lower ratio of caudate to posterior putamen (0.82 ± 0.03) 
than the young control group (0.87 ± 0.07; p = 0.036), but the 
decrease in the ratio in the control groups (-5.7%) was much 
smaller than the decrease in the PD groups (-21.1%).
The effect of age at onset of PD on the development of 
FOG
During the follow-up period, FOG developed in 14 of 66 pa-
tients in the young-onset PD group and in 24 of 73 in the old-
onset PD group. FOG occurrence over time in the PD groups is 
shown in Figure 1. Kaplan-Meier analysis revealed that the old-
onset PD group had a higher risk for developing FOG than the 
young-onset group (PLog-rank = 0.007). The Cox regression mod-
el revealed that patients in the old-onset PD group had a high-
er risk for developing FOG than those in the young-onset PD 
group [HR 2.523, 95% CI (1.239–5.140), p = 0.011, while adjust-
ing for DAT availability in the posterior putamen; HR 2.511, 
95% CI (1.175–5.366), p = 0.017, while adjusting for DAT avail-
ability in the caudate] (Table 2). Additionally, when the Cox re-
gression model was applied to the entire 205 patients with PD, 
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with age at PD onset as a continuous variable, the age at onset 
significantly affected the development of FOG [HR 1.041, 95% 
CI (1.010–1.074), p = 0.010, while adjusting for DAT availabili-
ty in the posterior putamen; HR 1.042, 95% CI (1.008–1.078), 
p = 0.016, while adjusting for DAT availability in the caudate], 
while the striatal DAT availability did not [posterior putamen, 
HR 1.033, 95% CI (0.514–2.074), p = 0.928; caudate, HR 1.033, 
95% CI (0.568–1.878), p = 0.916; Supplementary Table 2 in the 
online-only Data Supplement]. Thus, if a patient with PD exhib-
ited parkinsonian symptoms one year later, the patient had an 
approximately 4% higher risk for developing FOG.
The effect of age at onset of PD on the rate of 
longitudinal changes in LED
There was a significant time × PD group interaction in the 
mixed model (p < 0.001), indicating that the pattern of longitu-
dinal changes in LED differed between the young- and old-on-
set PD groups. Throughout the follow-up period, the old-onset 
PD group required higher doses of PD medications than the 
young-onset PD group for effective control of parkinsonian 
symptoms (Table 3, Figure 2).
DISCUSSION
In the present study, we investigated the effects of age at PD 
onset on the patterns of striatal dopamine depletion and long-
term motor outcomes in relation to the risk for developing FOG 
and longitudinal changes in LED over time. The major findings 
are summarized as follows: 1) Patients in the old-onset PD group 
had higher UPDRS-III scores than those in the young-onset 
PD group, despite comparable DAT availability in the posterior 
putamen; 2) The old-onset PD group exhibited more severely 
decreased DAT availability in the caudate than the young-on-
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Figure 1. Kaplan-Meier estimates curves of the development of 
FOG after onset of parkinsonian symptoms in patients with young-
onset PD (n = 66) and old-onset PD (n = 73). The old-onset group 
demonstrated a higher risk for developing FOG than the young-on-
set group (PLog-rank = 0.007). The crosses in the plots indicate cen-
sored data. FOG: freezing of gait, PD: Parkinson’s disease.
Table 1. Demographic characteristics of patients with PD
Young (n = 66) Old (n = 73) p-value
Age (yr) 52.58 ± 5.00 73.80 ± 4.94 < 0.001
Female, n (%) 33 (50.0) 36 (49.3) 0.936
PD onset age (yr) 51.15 ± 5.06 72.66 ± 4.71 < 0.001
PD duration (yr) 17.12 ± 14.51 13.77 ± 11.36 0.134
UPDRS-III 20.79 ± 9.68 24.26 ± 10.01 0.040
K-MMSE 27.58 ± 2.02 26.77 ± 1.78 0.013
Striatal DAT availability 
Anterior caudate 2.50 ± 0.70 1.91 ± 0.58 < 0.001*
Posterior caudate 1.55 ± 0.51 1.19 ± 0.40 < 0.001*
Anterior putamen 2.30 ± 0.59 2.07 ± 0.60 0.162*
Posterior putamen 1.25 ± 0.36 1.26 ± 0.49 > 0.999*
Ventral putamen 1.47 ± 0.33 1.36 ± 0.41 0.406*
Ventral striatum 2.48 ± 0.53 2.26 ± 0.58 0.125*
Ratio of caudate to posterior putamen 1.85 ± 0.47 1.46 ± 0.41 < 0.001
Values are expressed as the mean ± standard deviation or number (percentage). *Bonferroni correction for multiple comparisons. PD: Parkinson’s 
disease, UPDRS-III: Unified Parkinson’s Disease Rating Scale Part III, K-MMSE: the Korean version of the Mini-Mental State Examination, DAT: do-
pamine transporter.
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set PD group, while DAT availability in the other striatal subre-
gions did not differ between the groups; 3) Patients in the old-
onset PD group had a higher risk for developing FOG than 
those in the young-onset PD group; and 4) The old-onset PD 
group required higher doses of dopaminergic medications than 
the young-onset PD group throughout the follow-up period. 
These findings suggest that the onset of parkinsonian symp-
toms at older ages is associated with relatively diffuse striatal 
dopamine depletion and poorer long-term motor outcomes.
Selective dopaminergic denervation in the posterior putamen 
is the principal pathological feature of PD,20 although the exact 
pathogenic mechanisms underlying this regional selectivity re-
main unclear. Aside from the posterior putamen, other striatal 
subregions are also gradually affected in PD to various degrees 
with uncertain clinical relevance. Postmortem studies have re-
ported that patients with PD accompanied by disabling tremor 
exhibited greater dopamine neuronal loss in the retrorubral area 
(A8)9 but less in the substantia nigra pars compacta (A9)8 com-
pared to those without tremor as a dominant parkinsonian symp-
tom. Several PET studies have demonstrated that the extent of 
involvement of extra-putaminal subregions varies among pa-
tients with PD21,22 and have suggested a link between striatal do-
pamine loss pattern and clinical heterogeneity.12,23,24 Given that 
striatal dopamine deficiency represents the primary dysregula-
tion of neurotransmitter action in PD25 and that the striatum can 
be subdivided according to topographically and functionally 
organized connections,26 patterns of striatal dopamine depletion 
may reflect the clinical phenotypes of PD.
In this regard, a few pathological and PET/single-photon emis-
sion computed tomography studies have explored the relation-
ship between age at onset, clinical heterogeneity, and patterns of 
nigrostriatal dopamine deficit in patients with PD. A postmor-
tem study involving 12 young- and 22 old-onset cases of PD re-
ported greater nigral cell loss in the young-onset PD group, with-
out differences in basic Lewy body pathology.27 Two molecular 
imaging studies reported that patients with young-onset PD 
endured more damage to the nigrostriatal dopamine system at 
symptom manifestation than those with old-onset PD, suggest-
ing more efficient compensatory mechanisms in younger indi-
viduals,10,11 while other studies found no such association be-
tween age at onset and the severity of nigrostriatal damage.28-30 
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Figure 2. Longitudinal increases in levodopa-equivalent doses. The 
young-onset group received lower doses of dopaminergic medica-
tions for symptom control than the old-onset group. There was a 
significant interaction between groups and time in the mixed model 
(group × time: p < 0.001).
Table 2. Cox regression analysis for the development of freezing of gait according to the age at onset of parkinsonism
Factors
Posterior putamen Caudate
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Group (old vs. young) 2.523 (1.239, 5.140) 0.011 2.511 (1.175, 5.366) 0.017
Sex (female vs. male) 1.012 (0.509, 2.009) 0.974 1.018 (0.502, 2.065) 0.960
Mean DAT availability 1.034 (0.519, 2.060) 0.925 0.992 (0.554, 1.775) 0.978
LED 1.000 (0.999, 1.002) 0.610 1.000 (0.999, 1.002) 0.615
K-MMSE 0.974 (0.820, 1.157) 0.765 0.974 (0.821, 1.157) 0.766
DAT: dopamine transporter, LED: levodopa-equivalent dose, K-MMSE: the Korean version of the Mini-Mental State Examination, CI: confidence interval.
Table 3. Longitudinal changes in levodopa-equivalent dose
Young (n = 66) Old (n = 73) Overall p-value* p-value†
Month 6 282.68 (18.44) 440.34 (17.32) < 0.001
Month 12 314.24 (18.44) 474.36 (17.32) Group: < 0.001 < 0.001
Month 18 338.57 (18.44) 496.40 (17.32) Time: < 0.001 < 0.001
Month 24 349.09 (18.44) 516.82 (17.20) Group × Time: < 0.001 < 0.001
Month 30 369.69 (18.44) 532.97 (17.32) < 0.001
Month 36 400.51 (18.44) 548.11 (17.20) < 0.001
Values are expressed as the estimated mean (standard error) for the levodopa-equivalent dose. *p-values calculated by a linear mixed model analy-
sis, †group comparison at each time point.
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Recently, Liu et al.12 reported that the ratio of caudate/putamen 
DAT binding was lower in the old-onset PD group than in the 
young-onset PD group, although absolute DAT binding in the 
caudate and putamen did not differ between the groups. Paga-
no et al.13 also demonstrated more widespread dopaminergic 
dysfunction in elderly patients by analyzing data from the Par-
kinson’s Progression Marker Initiative (PPMI) database. In the 
present study, we classified patients with PD based on the dis-
tribution of age at onset in our database, and the cut-off ages to 
assign the patients to the young-onset PD group (i.e., 58 years) 
were much higher than in previous studies (i.e., most studies set 
the cut-off at 50 years of age). Nevertheless, our results are con-
sistent with two recent studies12,13 that reported more sparing of 
other striatal subregions than of the putamen in young-onset 
PD. This striatal dopamine loss pattern could be associated with 
some benign clinical features in younger patients, such as lower 
UPDRS-III scores and a slower rate of longitudinal increases in 
LED. In fact, some evidence has suggested that residual dopa-
mine in the spared associative/limbic striatum would compen-
sate for dopaminergic deficits in the sensorimotor striatum (i.e., 
posterior putamen) through sprouting of the remaining dopa-
minergic fibers or increased dopamine release and diffusion.31 
In addition, DAT availability in the caudate might be linked to 
cognitive function in the PD groups.32 Although it remains elu-
sive how age at onset affects the pattern of striatal dopamine loss 
in PD, some aging-dependent biological variables, such as neu-
ronal progenitor proliferation, trophic environment, inflamma-
tion, and proteasome/lysosome function,33 would be possible 
explanations.
In this study, patients with old-onset PD had a higher risk for 
developing FOG than the younger-onset patients. Given that 
FOG mostly occurs in the advanced stages of PD and that its 
appearance is associated with disease progression,19 our find-
ings support the concept that older age at onset is related to 
rapid disease progression.4 In fact, the risk factors for develop-
ing FOG have yet to be established; in particular, the effect of 
age at onset on the occurrence of FOG remains controversial.34-37 
Moreover, the underlying pathophysiology of FOG remains 
poorly understood, although some evidence has suggested that 
the dopaminergic component is a critical element for the devel-
opment of FOG.38 Further studies are needed to determine the 
associations among age at onset, patterns of striatal dopamine 
loss, and the development of FOG in patients with PD. In ad-
dition, the old-onset PD group exhibited a more rapid rate of in-
creases in LED than the young-onset PD group. Because the dose 
of dopaminergic medications is indirectly associated with par-
kinsonian disability,39 this result again suggests that age at onset 
is a key determinant of the rate of disease progression.
Some limitations of this study should be addressed. First, the 
patients were subdivided into tertile groups according to the 
distribution of age at onset, which may be somewhat arbitrary 
and may act as a bias. A consensus for the cut-off of ages to clas-
sify patients into young- versus old-onset groups is needed. Sec-
ond, FP-CIT PET may not be an ideal surrogate marker for ni-
grostriatal dopaminergic degeneration.40 Third, the occurrence 
of FOG was not assessed using objective gait measures or vali-
dated questionnaires, which may have led to an inaccurate esti-
mation of FOG. Fourth, there is a possibility that atypical par-
kinsonism cases (e.g., progressive supranuclear palsy with 
predominant parkinsonism) might be misdiagnosed as idio-
pathic PD, although we made a thorough diagnosis based on 
the appropriate criteria and evaluation. Finally, due to the lack 
of follow-up data on Hoehn and Yahr stage or UPDRS-III scores, 
we assessed the clinical progression based on the longitudinal 
changes in LED, which might not accurately reflect the motor 
status of patients with PD.
In conclusion, the present study demonstrated that subjects 
in the old-onset PD group exhibited more severe dopamine loss 
in the caudate and were more likely to develop gait freezing. 
These findings suggest that age at onset may be a major deter-
minant of the pattern of dopamine depletion and progression 
of gait disturbance in patients with PD.
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